How this fund's holdings score on the six lenses, weighted by holding weight — plus what the manager is actively buying and selling. A transparency roll-up of the stock atom — descriptive, not a forecast of outperformance.
What's a “leader”? A holding that ranks in the top two deciles (D9 / D10) of its size cohort on BOTH active conviction lenses — Technical and Flow. Leadership-breadth is the share of the fund's weight sitting in those leaders.
Risk & return
Compound returns and the risk taken to earn them, from the fund's own NAV history.
| Sector | 11 Jul | 18 Jul | 25 Jul | 24 Aug | 28 Aug | 04 Sep | Δ |
|---|---|---|---|---|---|---|---|
| Pharma | 60.1 | 60.7 | 60.7 | 61.3 | 61.3 | 61.3 | +1.2 |
| Healthcare | 34.6 | 34.3 | 34.3 | 35.2 | 35.2 | 35.2 | +0.6 |
| Digital | 0.3 | 0.3 | 0.3 | · | · | · | -0.0 |
| Financial Services | 1.4 | 1.5 | 1.5 | · | · | · | +0.1 |
Glass box
Click a lens to expand its holdings, ranked by contribution (weight × decile); each name links to its own evidence. Descriptive, not a forecast.
—
—
| Symbol | Sector | Weight | Tch | Fnd | Cat | Flw | Val | Lead | RS 3M |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | Pharma | 10.91% | 7 | 8 | 7 | 8 | 5 | — | +1.5% |
| APOLLOHOSP | Healthcare | 8.41% | 9 | 5 | 5 | 2 | 2 | — | +0.4% |
| CIPLA | Pharma | 6.92% | 4 | 3 | 6 | 4 | 7 | — | -3.9% |
| TORNTPHARM | Pharma | 4.50% | 7 | 8 | 5 | 4 | 1 | — | +7.0% |
| DIVISLAB | Pharma | 4.04% | 9 | 8 | 1 | 4 | 1 | — | +38.4% |
| AUROPHARMA | Pharma | 3.96% | 8 | 3 | 10 | 6 | 7 | — | +9.9% |
| MEDANTA | Healthcare | 3.61% | 8 | 9 | 5 | 4 | 2 | — | +13.1% |
| DRREDDY | Pharma | 3.59% | 2 | 2 | 6 | 10 | 9 | — | -14.7% |
| GLENMARK | Pharma | 3.50% | 10 | 9 | 9 | 4 | 3 | — | +8.2% |
| LALPATHLAB | Healthcare | 3.46% | 7 | 8 | 7 | 5 | 3 | — | +18.6% |
| MAXHEALTH | Healthcare | 3.44% | 1 | 9 | 6 | 5 | 6 | — | -6.0% |
| AJANTPHARM | Pharma | 2.93% | 8 | 10 | 1 | 3 | 3 | — | +13.9% |
| ZYDUSLIFE | Pharma | 2.80% | 9 | 10 | 10 | 2 | 8 | — | +1.9% |
| GLAXO | Healthcare | 2.49% | 8 | 7 | 2 | 8 | 4 | — | +31.0% |
| SHILPAMED | Pharma | 2.49% | 8 | 9 | 6 | 1 | 1 | — | +72.0% |
| RAINBOW | Healthcare | 2.39% | 10 | 7 | 4 | 3 | 4 | — | +5.0% |
| ABBOTINDIA | Pharma | 2.18% | 3 | 9 | — | 6 | 8 | — | -3.8% |
| HCG | Healthcare | 2.10% | 7 | 2 | 6 | 7 | 2 | — | +5.1% |
| PFIZER | Healthcare | 1.96% | 5 | 7 | 1 | 8 | 7 | — | -2.9% |
| SYNGENE | Healthcare | 1.93% | 1 | 2 | 6 | 7 | 7 | — | -17.8% |
| ERIS | Pharma | 1.92% | 3 | 8 | 4 | 9 | 8 | — | -7.4% |
| IPCALAB | Pharma | 1.92% | 9 | 5 | 1 | 3 | 4 | — | +14.3% |
| LUPIN | Pharma | 1.70% | 3 | 10 | 10 | 7 | 9 | — | -11.1% |
| ORCHPHARMA | Pharma | 1.70% | 7 | 1 | 4 | 10 | 2 | — | +8.0% |
| NH | Healthcare | 1.59% | 5 | 8 | 7 | 10 | 4 | — | -4.9% |
| NOVARTIND | Healthcare | 1.54% | 9 | — | — | 7 | 1 | Leader | +16.9% |
| SANOFI | Pharma | 1.45% | 2 | 6 | 3 | 8 | 9 | — | -5.7% |
| THYROCARE | Pharma | 1.45% | 7 | 10 | 8 | 9 | 2 | — | +1.4% |
| SAILIFE | Healthcare | 1.24% | 9 | 10 | 5 | 9 | 1 | Leader | +27.8% |
| ALIVUS | Pharma | 1.17% | 8 | 4 | 4 | 9 | 5 | — | +34.2% |
| MEDIASSIST | Healthcare | 1.01% | 4 | 7 | 9 | 8 | 7 | — | -8.2% |
| SAIPARENT | Pharma | 0.97% | 2 | 2 | 6 | 9 | 6 | — | -10.7% |
| VIYASH | Pharma | 0.77% | 8 | 8 | 8 | 6 | 2 | — | +0.3% |
| CONCORDBIO | Pharma | 0.44% | 8 | 4 | 2 | 5 | 3 | — | +16.2% |
Performance · 0.8y
Over the last 0.8 years ₹100 in the fund grew to ₹114 (+14%), vs ₹97 for Nifty 500 (−3%) and ₹91 for Nifty 50 (−9%). Its relative-strength line ended at 125 vs Nifty 50 and 117 vs Nifty 500 — above 100, sustained outperformance.